Por favor, use este identificador para citar o enlazar este documento: https://hdl.handle.net/2445/183735
Título: Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry
Autor: Figueras Roca, Marc
Parrado Carrillo, Alba
Nguyen, Vuong
Casaroli Marano, Ricardo Pedro
Moll Udina, Aina
Gillies, Mark C.
Barthelmes, Daniel
Zarranz Ventura, Javier
Materia: Oftalmopaties
Retina
Ophthalmopathies
Retina
Fecha de publicación: 20-nov-2020
Publicado por: Springer Verlag
Resumen: Purpose To compare the outcomes of two different antivascular endothelial growth factor treatment regimens for treatment-naive eyes with neovascular age-related macular degeneration in routine clinical care at 12 and 24 months in Spain. Methods Observational study using the Fight Retinal Blindness (FRB) outcomes registry platform. Eyes were treated with fixed bimonthly (FB) aflibercept group at one center and a treat-and-extend (TAE) regimen using either aflibercept or ranibizumab at the other center. Results We included 192 eyes. Of these, 160 eyes (83%) completed 12 months (86 TAE and 74 FB) and 79 (41%) completed 24 months (46 for TAE and 33 for FB) of follow-up. No statistically significant differences (p > 0.05) were found regarding mean visual acuity (VA, logMAR letters) at baseline (12 month cohort TAE 59.6 vs FB 57.9; 24 month cohort TAE 61.7 vs FB 62.6), final meanVA (12 month cohort TAE 61.1 vs FB 63.0; 24 month cohort TAE 64.8 vs FB 66.4), and median number of injections (12 months TAE 7 vs FB 7; 24 months TAE 11 vs FB 12). However, the distribution of injection frequencies for the TAE group was larger, with 35% of TAE eyes receiving ! 6 injections at 12 months compared with only 19% of FB eyes (p = 0.024). Conclusion Similar VA results were observed with TAE and FB regimens, with no differences in the median number of injections. However, the TAE approach seemed to deliver a wider distribution of injection frequencies due to its individualized approach, which may help reduce the burden of injections in some eyes.
Nota: Versió postprint del document publicat a: https://doi.org/10.1007/s00417-020-05016-9
Es parte de: Graefes Archive for Clinical and Experimental Ophthalmology, 2020, vol. 259, num. 4, p. 1-8
URI: https://hdl.handle.net/2445/183735
Recurso relacionado: https://doi.org/10.1007/s00417-020-05016-9
ISSN: 0721-832X
Aparece en las colecciones:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Archivos de este documento:
Archivo Descripción DimensionesFormato 
710226.pdf400.06 kBAdobe PDFMostrar/Abrir


Este documento tiene todos los derechos reservados